A Study to Investigate FP002 in Subjects With Advanced Malignancies
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: FP002 Injection
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Guangdong Fapon Biopharma Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT05982080
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Shangdong Cancer Hospital & Institute, Jinan, Shangdong, China
🇨🇳Linyi Cancer Hospital, Linyi, Shangdong, China
© Copyright 2025. All Rights Reserved by MedPath